Literature DB >> 19282307

Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women.

A M Delgado-Vega1, J Castiblanco, L M Gómez, L-M Diaz-Gallo, A Rojas-Villarraga, J-M Anaya.   

Abstract

OBJECTIVE: Bcl-2 antagonist killer 1 (BAK1) is a Bcl-2 family proapoptotic member suggested as a candidate gene for autoimmune diseases. The influence of BAK1 polymorphisms on the risk of developing autoimmune rheumatic diseases (AIRDs) in women was investigated.
METHODS: A total of 719 Colombian women were included in the present study: 209 had systemic lupus erythematosus, 99 primary Sjögren syndrome, 159 rheumatoid arthritis and 252 were healthy matched controls. Tag single nucleotide polymorphisms (SNPs) and potentially functional variants were typed by TaqMan allele discrimination assays. HLA-DRB1 and HLA-DQB1 typing was performed by reverse dot-blot hybridisation and linkage disequilibrium (LD) with BAK1 SNPs was assessed.
RESULTS: SNPs rs513349 (odds ratio (OR) 0.57, 95% CI 0.46 to 0.72, p = <0.001) and rs5745582 (OR 1.61, 95% CI 1.26 to 2.04, p = <0.001) were associated with the AIRDs included in this study. There was a significant increase of the rs513349G-rs561276C-rs5745582A (GCA) haplotype in each patient cohort as compared to controls (OR 1.95, 95% CI 1.50 to 2.54, p = <0.001). These SNPs were not in LD with HLA-DRB1 or HLA-DQB1 genes.
CONCLUSIONS: The results indicate that the BAK1 polymorphisms influence the risk of acquiring AIRDs in the population studied and are consistent with the paradigm that autoimmune diseases are likely to share common susceptibility variants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282307     DOI: 10.1136/ard.2008.100818

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases.

Authors:  Amit K Maiti; Xana Kim-Howard; Parvathi Viswanathan; Laura Guillén; Xiaoxia Qian; Adriana Rojas-Villarraga; Celi Sun; Carlos Cañas; Gabriel J Tobón; Koichi Matsuda; Nan Shen; Alejandra C Cherñavsky; Juan-Manuel Anaya; Swapan K Nath
Journal:  Rheumatology (Oxford)       Date:  2010-03-24       Impact factor: 7.580

2.  Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease.

Authors:  Kylie D Mason; Ann Lin; Lorraine Robb; Emma C Josefsson; Katya J Henley; Daniel H D Gray; Benjamin T Kile; Andrew W Roberts; Andreas Strasser; David C S Huang; Paul Waring; Lorraine A O'Reilly
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-24       Impact factor: 11.205

3.  Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy.

Authors:  M Iwaszko; J Świerkot; K Kolossa; S Jeka; P Wiland; K Bogunia-Kubik
Journal:  Clin Exp Immunol       Date:  2015-09-28       Impact factor: 4.330

Review 4.  The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases.

Authors:  Carla M Cuda; Richard M Pope; Harris Perlman
Journal:  Nat Rev Rheumatol       Date:  2016-08-23       Impact factor: 20.543

5.  An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren's Syndrome Patients.

Authors:  Orsia D Konsta; Christelle Le Dantec; Amandine Charras; Wesley H Brooks; Marina I Arleevskaya; Anne Bordron; Yves Renaudineau
Journal:  Front Immunol       Date:  2015-08-26       Impact factor: 7.561

Review 6.  Life and Death of Activated T Cells: How Are They Different from Naïve T Cells?

Authors:  Yifan Zhan; Emma M Carrington; Yuxia Zhang; Susanne Heinzel; Andrew M Lew
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.